AI in oncology market seen topping $10.25 billion by 2030

The artificial intelligence in oncology market is forecast to surge from $2.35 billion in 2025 to $10.25 billion by 2030, driven by rising cancer cases, precision medicine demand and wider use of AI in diagnostics and drug development. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - AI is moving deeper into cancer care, with applications in diagnosis, treatment planning, research and clinical decision-making. - The market’s rapid growth points to stronger demand for tools that can support more personalized and efficient oncology care. - Rising cancer incidence is increasing pressure on health systems to adopt faster and more accurate diagnostic and treatment technologies.

What happened: - The artificial intelligence in oncology market was estimated at $2.35 billion in 2025 and is projected to reach $3.13 billion in 2026. - The market is forecast to grow to $10.25 billion by 2030, reflecting a 34.5% CAGR from 2026 to 2030. - North America held the largest regional share in 2025. - Asia-Pacific is expected to post the fastest growth during the forecast period.

The details: - The market’s growth is tied to higher cancer rates worldwide, advances in oncology research and broader adoption of digital pathology. - Data-driven cancer diagnostics and investment in advanced oncology infrastructure are also supporting expansion. - The report points to precision oncology, personalized cancer treatments and AI use in clinical oncology trials as major demand drivers. - Deeper integration of genomics with AI platforms is expected to expand use cases. - AI-powered cancer detection, treatment planning, drug discovery, predictive oncology analytics and precision oncology applications are listed as key trends. - The report defines AI in oncology as the use of AI technologies to improve cancer diagnosis, treatment, research and patient care. - AI is intended to identify complex patterns, predict outcomes and support clinical decisions across the cancer care pathway. - In 2023, the American Cancer Society reported U.S. new cancer cases rising from 1.8 million to 1.9 million. - The market analysis covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The report also highlights added strategic tools, including market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspots infographics and updated graphics and tables.

Between the lines: - The forecast suggests oncology AI is shifting from a niche technology play to a broader commercial category tied to core cancer-care workflows. - Growth is not just coming from diagnostics; drug discovery, genomics and trial support are becoming part of the commercial opportunity. - The regional split suggests mature markets are leading adoption now, while faster growth in Asia-Pacific may reflect expanding healthcare digitization and unmet cancer-care demand.

What's next: - Wider adoption of AI tools in clinical workflows is likely as hospitals and research groups seek faster diagnosis and more tailored treatment plans. - Additional funding for AI-focused oncology startups may accelerate product development and commercialization. - The report expects continued momentum as precision oncology and predictive analytics become more central to cancer care. - More information is available in the full report and a free sample.

The bottom line: - AI in oncology is moving fast, and the market forecast signals a major shift toward data-driven cancer care.